125516 Apr 2026

It is typically administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA).

It is a chimeric GD2-binding monoclonal antibody that helps the immune system identify and destroy neuroblastoma cells. 125516

It is specifically indicated for the treatment of pediatric patients with high-risk neuroblastoma . 125516